Cardiovascular Clinical Trial
Official title:
A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects
Verified date | April 2019 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to assess the safety and tolerability of AMG 529 following single, ascending doses administered subcutaneously (SC) or intravenously (IV) in healthy adults.
Status | Completed |
Enrollment | 48 |
Est. completion date | November 17, 2017 |
Est. primary completion date | November 17, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Healthy men and women = 18 to = 55 years old with no history or evidence of clinically relevant medical disorders 2. Body mass index (BMI) between 18 and 32 kg/m², inclusive, at screening 3. Women must be of non-reproductive potential as defined in protocol 4. Other inclusion criteria may apply Exclusion Criteria: 1. Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives (whichever is longer), since ending treatment on another investigational device or drug study(s) prior to receiving the first dose of investigational product 2. Women who are lactating/breastfeeding or who plan to breastfeed while on study through 90 days after receiving the dose of investigational product 3. Men with partners who are pregnant or planning to become pregnant while the subject is on study through 90 days after receiving the dose of investigational product 4. Positive pregnancy test at screening or day -1 5. Other exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Events (AEs) | Determination of the severity of adverse events was according to the following: grade 1 = mild (eg, asymptomatic or mild symptoms); grade 2 = moderate (eg, minimal intervention indicated or interferes with activity); grade 3 = severe (eg, medically significant but not immediately life-threatening, prevents daily activity, or requires treatment); grade 4 = life-threatening (ie, refers to an event in which the participant was, in the view of the investigator, at risk of death at the time of the event); and grade 5 = fatal. A serious adverse event was defined as an adverse event that met at least 1 of the following criteria: fatal life threatening required in patient hospitalization or prolongation of existing hospitalization resulted in persistent or significant disability/incapacity congenital anomaly/birth defect other medically important serious event. |
From first dose up to 30 days for participants assigned to the 21 mg or 70 mg dose cohorts and up to 57 days for participants assigned to the 210 mg, 420 mg, or 700 mg dose cohorts. | |
Secondary | Maximum Observed Concentration (Cmax) of AMG 529 | Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts. | ||
Secondary | Time to Maximum Observed Concentration (Tmax) of AMG 529 | Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts. | ||
Secondary | Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529 | Predose and at 0.5 and 1 hour postdose (IV cohort only) and 6, 12, 24, 36, 48, 72, 120, 168, 240, 366, 504, and 696 hours postdose (all participants) and additionally at days 43 and 57 for participants assigned to the 210, 420, or 700 mg dose cohorts. | ||
Secondary | Change From Baseline in Blood Alkaline Phosphatase Concentration Over Time | Baseline and days 3, 8, and 30 | ||
Secondary | Change From Baseline in Total Cholesterol Concentration Over Time | Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts. | ||
Secondary | Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration Over Time | Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts. | ||
Secondary | Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) Concentration Over Time | Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts. | ||
Secondary | Change From Baseline in Triglycerides Concentration Over Time | Baseline and days 3, 6, 11, 22, 30 (all participants), and day 57 for participants assigned to the 210 mg, 420 mg, or 700 mg cohorts. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236337 -
Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit!
|
N/A | |
Completed |
NCT03236363 -
Effectiveness of MOVI Interventions on Adiposity, Cognition and Motor Competence: MOVI-da10!
|
N/A | |
Completed |
NCT01304641 -
Cardiovascular Events Based On Statin Initiation In The Elderly
|
||
Terminated |
NCT03277183 -
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
|
Phase 4 | |
Not yet recruiting |
NCT05316025 -
Cardiovascular Digital Health Data Observatory
|
||
Recruiting |
NCT05775484 -
Exercise to Slow Cardiovascular Ageing Progression
|
||
Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT04863040 -
The Impact of Activity Breaks on Cognitive Function, Adiposity and Fitness in Preschoolers
|
N/A | |
Not yet recruiting |
NCT04866732 -
Physical Activity Program for Cardiac Health Among Older African American Populations
|
N/A | |
Recruiting |
NCT05568966 -
Collection of Blood Samples for New Diagnostic Devices 2
|
N/A | |
Recruiting |
NCT01820598 -
Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients
|
N/A | |
Completed |
NCT00824330 -
Home-Based Walking Study in Older Adults With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06238466 -
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
|
Phase 1 | |
Completed |
NCT00387452 -
Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05249296 -
The Impact of Green Spaces on the General Well-being and Stress of Students
|
N/A | |
Completed |
NCT01232309 -
Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)
|
N/A | |
Completed |
NCT01489696 -
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
|
Phase 1 | |
Completed |
NCT00954902 -
Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)
|
N/A | |
Completed |
NCT04216238 -
Association of Wearable Activity Monitors With Post-Operative Activity Level Among Cardiovascular Surgical Patients
|
||
Completed |
NCT04121416 -
Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery
|
N/A |